Kenneth J. Rhodes

Boston University — United States

Neuroscience · Life Sciences

46h-index11.5kcitations402works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroscience and Neuropharmacology Research(35), Ion channel regulation and function(33), Cardiac electrophysiology and arrhythmias(22), Pharmacological Effects and Toxicity Studies(19), Electroconvulsive Therapy Studies(14)

Publications402 total

Patient-derived three-dimensional cortical neurospheres to model Parkinson’s disease
PLoS ONE·2022· 15 citedOpen Access
Automated algorithm development to assess survival of human neurons using longitudinal single-cell tracking: Application to synucleinopathy
SLAS TECHNOLOGY·2022· 2 citedOpen Access
Correction to: A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
Neurotherapeutics·2022· 3 citedOpen Access
A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
Neurotherapeutics·2022· 22 citedOpen Access
Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson’s Disease
Molecular Neurobiology·2022· 30 citedOpen Access
Patient-Derived Three-Dimensional Cortical Neurospheres to Model Parkinson’s Disease
2021· 4 citedOpen Access
Inhibiting Stearoyl-CoA Desaturase Ameliorates α-Synuclein Cytotoxicity
Cell Reports·2018· 130 citedOpen Access
Potent PDZ-Domain PICK1 Inhibitors that Modulate Amyloid Beta-Mediated Synaptic Dysfunction
Scientific Reports·2018· 26 citedOpen Access
Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation
Journal of Biological Chemistry·2017· 171 citedOpen Access
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Nature·2017· 72 citedOpen Access
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Nature·2016· 3.0k cited
P1‐033: Aducanumab Targets High Molecular Weight Soluble Aβ Oligomers and Restores Calcium to Normal Levels in TG2576 Mice
Alzheimer s & Dementia·2016
Pharmacodynamics of Dimethyl Fumarate Are Tissue Specific and Involve NRF2-Dependent and -Independent Mechanisms
Antioxidants and Redox Signaling·2016· 57 cited
Human-derived monoclonal antibodies for Alzheimer’s disease and related proteinopathies
Neurobiology of Aging·2016
BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease
Neuropharmacology·2015· 14 cited
Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro
PLoS ONE·2015· 169 citedOpen Access
Neuroprotectants: Novel Approaches for Dementias
2015
JNJ-40255293, a Novel Adenosine A<sub>2A</sub>/A<sub>1</sub>Antagonist with Efficacy in Preclinical Models of Parkinson’s Disease
ACS Chemical Neuroscience·2014· 41 cited
Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Pharmacodynamic Effects and Pharmacokinetics In Vivo (P1.207)
Neurology·2014
Dimethyl Fumarate and Monomethyl Fumarate are Distinguished by Non-Overlapping Pharmacodynamic Effects In Vivo (P1.206)
Neurology·2014· 5 cited
page 1 of 21Next →

Frequent Co-authors

James S. Trimmer(21), Robert H. Scannevin(16), Wiepke Cahn(8), Michael M. Monaghan(8), Brian W. Strassle(6), María Isabel Colado(6), Daniel Bertrand(6), Hans Rollema(6), H D Postma(6), Zewditu Bekele-Arcuri(6), Maria F. Matos(6), Karen Carroll(6), Paul Jackson(6), Wei An(5), Heleen B. M. Boos(5), Melanie S. Brennan(4), Jie Cao(4), Kensuke Nakahira(4), Greg A. Gerhardt(4), Lynette C. Daws(4)